The judges said the ruling would not "open the floodgates" as only women who met the clinical criteria for Herceptin would qualify for the drug.
Swindon PCT had argued that it would only fund the drug for patients in "exceptional circumstances", and that the drug was not licensed for the treatment of early-stage breast cancer, which is the kind Ms Rogers has.
But the Court of Appeal judges ruled that the PCT's policy was "irrational and unlawful".
They ruled that the focus should be what a doctor felt was right for their patient.
They ruled that: "In the case of personal characteristics, there is no rational basis for preferring one patient to another".
Ms Rogers, said she was "extremely delighted and relieved" at the Appeal Court's "humanitarian" judgement.
From now on treatment should depend on clinical need and not on where you live
"I couldn't have asked for a better verdict. I did this for all women battling this dreadful disease. I believe everyone prescribed this treatment by their doctor should be given the same health care wherever they live. I can now look forward to the future and have more confidence that I will win this battle against breast cancer."
Yogi Amin, of solicitors, Irwin Mitchell, who represented Ms Rogers, said "This truly landmark judgement makes clear to PCTs that they cannot overlook the clinical needs of the patient.
"People need to be confident that they will receive the drugs their doctor prescribes for them and it is therefore good news for doctors and patients alike."
He said ministers now needed to set out clear guidance on how drugs should be funded by PCTs.
In a statement, Swindon PCT said: "Although the judgement said generally our policy on funding is lawful, we accept that when considering this case and exceptional circumstances we should have taken costs into account to make our decision more rational."
It said it would consider its policy, taking into consideration the points made by the court.
Herceptin targets the HER-2 protein, which can fuel the growth of breast tumours. Around a fifth of breast cancers are HER-2 positive. A year's treatment with the drug costs an estimated £20,000.
The treatment is currently licensed for the treatment of advanced breast cancer but not for early-stage breast cancer, which research has suggested it could also help.
Makers Roche submitted their licence application for early-stage breast cancer to European drug authorities in February.
Once that is granted, NHS drugs watchdog the National Institute for Health and Clinical Excellence (NICE) promised to fast-track its appraisal if Herceptin is cost-effective
That process is set to be completed later this year.
Jeremy Hughes, Chief Executive of Breakthrough Breast Cancer said: "From now on treatment should depend on clinical need and not on where you live, how much money you have, or how "exceptional" you are.
"Today's decision is a real victory for the 1,000 women whose lives could be saved by this drug each year."
A Department of Health spokeswoman said the judgement provided clarification to PCTs.
"As is the case with other unlicensed drugs, clinicians can take the decision to prescribe Herceptin to patients with HER2 positive early breast cancer.
She said PCTs should not rule out treatments on principle, but consider individual circumstances when reaching decisions and should not refuse to fund Herceptin solely on the grounds of cost of the drug. This position remains unchanged.